For a wider look at product strategy in US approvals and sales, see If you want blockbuster sales, buy them in, April 29, 2019.
For more on Q1 2019 share price performances see: Topsy turvy times for industry’s mid and small cap stocks in the first quarter and US big biotechs lag in the opening quarter of the year
For further analyses on recent M&A deals see: Following the M&A money, by phase and therapy area, January 29, 2019.
Right click and open in new tab to enlarge.
For more on 2018's venture financing see: Another strong quarter from the venture world, October 01, 2018.
For more on the subject of biggest launches see our article from February: The biggest drug launches – hep C dominates but Tecfidera stands out, February 21, 2018